Facebook Twitter RSS Feed

You are here

Vascular & Endovascular

 - Brain, neuro, carotid stenting

Carotid artery stenting (CAS) may benefit patients by reducing stroke risks in the long term, but recent data suggest that they may not be living long enough for that benefit to bear fruit. According to a study published online Jan. 12 in JAMA Neurology, 32 percent of elderly CAS patients died within two years of the procedure.

 - blood cells

The FDA followed the advice of its advisory panel and added another novel oral anticoagulant to its approved drug list.

 - Gavel and stethoscope

The Department of Justice (DoJ) is taking the reins in two lawsuits filed against a Florida cardiologist who made headlines in 2014 for billing Medicare $18 million in one year. The DoJ alleges he performed medically unnecessary interventions and paid kickbacks to patients.

 - Thumbs_Up

The FDA approved Medtronic’s drug-coated balloon as a treatment for peripheral artery disease (PAD), giving physicians more options for treating patients with disease in the superficial femoral artery and the popliteal artery.

 - High blood pressure, hypertension

A meta-analysis of blood pressure monitoring studies supports closely monitoring patients at risk for hypertension and cardiovascular disease. This included support for using ambulatory methods on patients in order to prevent overdiagnosis due to office-related elevated blood pressure.


More Stories

Circling back to ORBIT-AF: Bridging anticoagulation may increase bleeding, adverse events risk

Before you cross that bridge, consider: A fresh look at the data from ORBIT-AF suggests that bridging oral anticoagulation instead of temporary cessation for a procedure may put patients at greater risk for bleeding or adverse events.

Deep dive into HTN-3 helps ID ways to improve

What, if anything, went wrong in the SYMPLICITY HTN-3 trial will probably remain up for debate, but a post hoc analysis may help to keep subsequent trials on the right path.

Risk of VTE increases with duration of surgery

Consider it one more reason to make that surgery a quick one. Researchers found that the longer a surgery goes, the more risk of venous thromboembolism (VTE) for the patient. 

ZOLL snaps up Philips’ InnerCool assets

ZOLL Medical is buying the assets from Philips’ InnerCool temperature management business, which includes several products cleared for use in the U.S.

Low-dose aspirin fails to impress in Japanese study

A subgroup analysis eventually may offer answers in a trial that assessed once-daily, low-dose aspirin to prevent atherosclerotic cardiovascular disease in Japan, according to a study published online Nov. 17 in JAMA. The trial was terminated early due to futility.

VIVA.14: Promising 1-year results for drug-coated balloons in diabetics

Patients with peripheral artery disease (PAD) and diabetes who underwent treatment with a drug-coated balloon fared better than counterparts who received standard care, according to a subanalysis of the IN.PACT SFA trial.

VIVA.14: Zilver PTX holds strong at five years

At five years, the Zilver PTX stent proved to be a durable treatment for peripheral artery disease with sustained benefit, results presented Nov. 4 at the 2014 Vascular Interventional Advances (VIVA) meeting showed.

VIVA.14: DISRUPT PAD brings lithoplasty technique to peripheral lesions

Shockwaves appear to have early success in breaking up calcified lesions safely. In research presented Nov. 5 at the 2014 Vascular Interventional Advances (VIVA) meeting in Las Vegas, a lithotripsy-with-balloon technique used on peripheral artery lesions resulted in all patients achieving less than 50 percent stenosis. 

Spectranetics offers $30M for PAD balloon

Spectranetics will pay $30 million to acquire a drug-coated angioplasty balloon platform from Covidien, if the transaction passes muster with regulators.

FDA panel supports edoxaban for stroke prevention

An FDA advisory panel voted 9-1 in favor of approval of the anticoagulant edoxaban to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Trial seeks best outcomes in midgrade SFA PAD

When a patient’s peripheral artery disease (PAD) is in the middle of two extremes, which is the best method of treatment: open bypass or angioplasty and stenting? A randomized trial is under way to compare treatment outcomes for patients with the middle two tiers of PAD in the superficial femoral artery (SFA). 

Complex patients less likely to die at high-volume stroke centers

Brain hemorrhage survival was highest among patients taken to high-volume stroke care units, according to findings published in the November issue of Neurosurgery. Comprehensive stroke centers and other high-volume stroke care units had the fewest subarachnoid hemorrhage in-hospital deaths, researchers found. 

FDA OKs stent system for peripheral disease

The FDA approved the Ever-Flex Self-Expanding Peripheral Stent System for use in the common and external iliac arteries.

Lowering blood pressure has no effect on stroke outcomes

Blood pressure may not be the key to improving stroke outcomes after all. In an international study published online Oct. 22 in The Lancet, stroke patients randomized to have blood pressure control within 48 hours of infarct did no better than patients whose high blood pressure remained untreated. They did no worse, either. 

EVAR trial results don't sync with real-world outcomes

Endovascular aneurysm repair (EVAR) has a lower 30-day mortality rate than open abdominal aortic aneurysm (AAA) surgery in trials, but rates may not be as low in a real-world setting. Researchers who compared findings from a national clinical database against a recent trial believe the difference may be in the patient cohort’s pre-existing health status.

DEB diverts recurrent in-stent carotid artery restenosis long term

Drug-eluting balloons (DEBs) gave patients with early, recurrent and significant in-stent carotid artery restenosis longer freedom from restenosis in a trial published in the October issue of the Journal of Endovascular Therapy. More than half of patients in this small cohort were symptom-free at a mean follow-up of 36.6 months.

The carotid conundrum

It may look like a fielder’s choice between carotid artery stenting and endarterectomy for patients with carotid artery stenosis, with conclusions from one recent analysis and another randomized trial leaning in opposite directions. 

Surgery vs. stents: Both effective for treating carotid artery stenosis

In the battle between endarterectomy and carotid artery stenting, the patient emerged as the ultimate victor in a study published online Oct. 14 in The Lancet. Both approaches proved to be equally effective at preventing severe stroke at 10 years, giving physicians a green light to choose the treatment that best fits the individual patient.

No equipoise, just better outcomes found in CEA over CAS

Atherosclerotic patients in a real-world setting did better when carotid endarterectomy (CEA) was used as opposed to carotid angioplasty and stenting (CAS). Contradictory to some earlier prospective studies, at no point did researchers find equipoise between the two procedures. 

1 in 5 at-risk stroke patients meet low LDL targets

Efforts to bring low-density lipoprotein (LDL) cholesterol levels within guideline parameters fall short with stroke. Only one in five patients at high risk for recurrent stroke met recommendations for LDL cholesterol levels below 70 mg/dL, according to results published online Oct. 9 in Stroke.